Exagen Stock News

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December

SAN DIEGO, March 08, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, will release financial results for the quarter and year ended December 31

MacroGenics (MGNX) delivered earnings and revenue surprises of -14.46% and 28.67%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the BTIG MedTech, Digital Health, L

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a

SAN DIEGO, Jan. 09, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (NASDAQ: XGN ), a leading provider of autoimmune testing solutions, and Queen Mary University of London, announced today the execution of a research collaboration and exclusive license agreement. The collaboration will focus on development and optimization of patent-pending precision medicine approaches, based on RNA expression signatures, to personalize therapeutic agent selection for rheumatoid arthritis (RA) patients. Both parties will contribute to the development of the patent-pending assays, leading to the commercialization of novel molecular assays that segment patients according to gene expression in their synovial tissue biopsies. RA is estimated to affect approximately two million patients in the United States and be twice as prevalent in women as in men and can be difficult to manage due to the variability in treatment response from patient to patient. Therapeutic agent selection for RA patients remains a significant unmet need.

Cowen Prime Advisors LLC acquired a new position in shares of Exagen Inc. (NASDAQ:XGN) in the 3rd quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 182,900 shares of the companys stock, valued at approximately $2,487,000. Cowen Prime Advisors LLC owned approximately 1.13% of Exagen as of its most recent []

Analysts expect Exagen Inc. (NASDAQ:XGN) to announce sales of $11.80 million for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Exagens earnings. The lowest sales estimate is $11.30 million and the highest is $12.30 million. Exagen reported sales of $12.67 million during the same quarter last year, which indicates []

Equities research analysts expect Exagen Inc. (NASDAQ:XGN) to announce ($0.50) earnings per share for the current quarter, Zacks reports. Two analysts have issued estimates for Exagen’s earnings, with the highest EPS estimate coming in at ($0.49) and the lowest estimate coming in at ($0.50). Exagen posted earnings of ($0.27) per share in the same quarter […]

Morgan Stanley lifted its position in Exagen Inc. (NASDAQ:XGN) by 269.1% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 364,864 shares of the companys stock after buying an additional 266,001 shares during the period. Morgan Stanleys holdings in Exagen were worth []

California State Teachers Retirement System lifted its holdings in Exagen Inc. (NASDAQ:XGN) by 105.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 14,849 shares of the companys stock after purchasing an additional 7,630 shares during the period. California State Teachers Retirement System []

Charles Schwab Investment Management Inc. raised its holdings in shares of Exagen Inc. (NASDAQ:XGN) by 164.1% during the second quarter, HoldingsChannel.com reports. The firm owned 27,074 shares of the companys stock after acquiring an additional 16,821 shares during the quarter. Charles Schwab Investment Management Inc.s holdings in Exagen were worth $406,000 at the end of []

Nuveen Asset Management LLC grew its stake in Exagen Inc. (NASDAQ:XGN) by 172.0% in the second quarter, HoldingsChannel.com reports. The institutional investor owned 30,980 shares of the companys stock after buying an additional 19,592 shares during the period. Nuveen Asset Management LLCs holdings in Exagen were worth $465,000 as of its most recent filing with []

Wall Street brokerages predict that Exagen Inc. (NASDAQ:XGN) will report $11.80 million in sales for the current quarter, according to Zacks Investment Research. Two analysts have issued estimates for Exagens earnings, with estimates ranging from $11.30 million to $12.30 million. Exagen reported sales of $12.67 million during the same quarter last year, which would suggest []

SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing solutions, today announced its participation in the Piper Sandler 33rd Annual Virtu